Develops tumor treating fields (TTFields) therapy for cancer treatment, focusing on non-invasive cancer treatment options.
NovoCure Limited operates as a leading oncology company dedicated to advancing the field of cancer treatment through innovative therapies. Specializing in tumor treating fields (TTFields) devices, the company focuses on developing, manufacturing, and globally commercializing its transformative technologies. These devices, including Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma, harness electrical fields to disrupt cancer cell division, offering new avenues for patients battling solid tumor cancers across the United States, Europe, the Middle East, Africa, Japan, and Greater China.
In addition to its established therapies, NovoCure Limited is actively involved in ongoing clinical trials and research initiatives. These efforts explore the potential applications of TTFields in various challenging cancer types, such as brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. By continually expanding its clinical portfolio, NovoCure seeks to broaden the therapeutic options available to oncology patients worldwide, aiming to improve outcomes and quality of life.
Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure Limited exemplifies a commitment to innovation and patient-centric care in oncology. With a strong foundation in research and development, the company remains at the forefront of pioneering TTFields technology, striving to redefine cancer treatment paradigms and bring hope to patients and their families globaly.